Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Tangshan
Clinical trial register · China

Clinical Trials in Tangshan, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19282 matching records held by the registry are in this view. Synced 15 Nov 2026, 03:17 UTC
19282
Studies in scope
all four open statuses
11840
Recruiting now
open to new participants
2032
Lead sponsors
across recruiting studies
Top sites
Beijing 5606 Shanghai 3892 Guangzhou 3359 Hangzhou 1833 Wuhan 1342
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Peking Union Medical College Hospital3 Nanjing RegeneCore Biotech Co., Ltd.2 Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.2 Jiangsu BioJeTay Biotechnology Co., Ltd.2 Capital Medical University2 Chia Tai Tianqing Pharmaceutical Group Co., Ltd.2 European Myeloma Network B.V.1 Peking University Hospital of Stomatology1 Novartis Pharmaceuticals1 Beijing Friendship Hospital1 Yan Zhang1 Shanghai Xinzhi BioMed Co., Ltd.1 Huazhong University of Science and Technology1 Beijing Tiantan Hospital1 Green Valley (Shanghai) Pharmaceuticals Co., Ltd.1 Gritgen Therapeutics Co., Ltd.1 Tangshan People's Hospital1 Second Xiangya Hospital of Central South University1 CASI pharmaceuticals, Inc.1 Zhongshan Sansure Hygene Biomedicine Co., Ltd.1 Seagen, a wholly owned subsidiary of Pfizer1 Dermavon Holdings Limited1 China National Center for Cardiovascular Diseases1 Tianjin Medical University General Hospital1 Hangzhou Sumgen Biotech Co., Ltd.1 Show all 28
Site location
Beijing5606 Shanghai3892 Guangzhou3359 Hangzhou1833 Wuhan1342 Chengdu1310 Nanjing1216 Changsha1159 Chongqing1085 Fuzhou1041 Tianjin940 Zhengzhou926 Hefei909 Jinan794 Changchun642 Shenzhen585 Harbin549 Nanchang449 Nanning443 Xi'an443 Suzhou433 Shenyang406 Xiamen391 Shijiazhuang351 Lanzhou273 Show all 625
All 625 locations
Target enrolment
to

Trials with a site in Tangshan

35 of 19282 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Chinese PLA General Hospital
Phase 3
120
Beijing, Tangshan, Taiyuan
2026-10-12
Not yet open
PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke
NCT07466251Acute Ischemic Stroke AIS, Intracranial Atherosclerosis ICAS, Atherosclerotic Plaque
DrugRecaticimab
Peking Union Medical College Hospital
Phase 4
1,212
Beijing, Meizhou, Cangzhou, Qinhuangdao, Shijiazhuang, Tangshan, Harbin, Zhengzhou
2026-09-01
Not yet open
Zhongshan Sansure Hygene Biomedicine Co., Ltd.
Phase 3
240
Hefei, Beijing, Xiamen, Guangzhou, Tangshan, Wuhan, Changsha, Nanjing
2026-09
Recruiting
Hangzhou Sumgen Biotech Co., Ltd.
Phase 2
60
Fuzhou, Guangzhou, Liuzhou, Yulin, Baoding, Chengde, Tangshan, Harbin
2026-06-11
Not yet open
Peking Union Medical College Hospital
Observational
2,000
Hefei, Beijing, Linxia, Qinzhou, Guiyang, Zunyi, Tangshan, Mudanjiang
2026-05-30
Recruiting
Capital Medical University
Phase 3
348
Huaibei, Suzhou, Heyuan, Maoming, Qinhuangdao, Tangshan, Anyang, Hebi
2026-04-22
Not yet open
Dermavon Holdings Limited
Phase 2
160
Beijing, Fuzhou, Guangzhou, Shenzhen, Haikou, Shijiazhuang, Tangshan, Zhengzhou
2026-03-20
Recruiting
Phase II Trial of RC1416 Injection in Asthma
NCT07403487Moderate to Severe Asthma
DrugRC1416
Nanjing RegeneCore Biotech Co., Ltd.
Phase 2
195
Anqing, Suzhou, Beijing, Chongqing, Lanzhou, Shijiazhuang, Tangshan, Xingtai
2026-03-10
Recruiting
Tianjin Medical University General Hospital
Phase 4
320
Baoding, Tangshan, Tianjin
2026-01-06
Recruiting
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1
42
Chongqing, Guangzhou, Chengde, Tangshan, Nanjing, Suzhou, Nanchang, Xi'an
2025-12-09
Active, closed
Capital Medical University
Phase 3
692
Suzhou, Zhangzhou, Qinzhou, Langfang, Qinhuangdao, Tangshan, Harbin, Anyang
2025-12-05
Recruiting
Shanghai RAAS Blood Products Co., Ltd.
Phase 2
24
Changsha, Hefei, Jinan, Nanning, Suzhou, Taiyuan, Tangshan, Tianjin
2025-11-26
Recruiting
PCSK9 Inhibitor With Statin Therapy for Asymptomatic Intracranial Atherosclerosis
NCT06902740Intracranial Atherosclerosis, Intracranial Artery Stenosis, Atherosclerotic Plaque
Peking Union Medical College Hospital
Phase 4
300
Beijing, Meizhou, Cangzhou, Qinhuangdao, Shijiazhuang, Tangshan, Harbin, Zhengzhou
2025-11-07
Recruiting
Tangshan People's Hospital
Not applicable
99
Tangshan
2025-10-01
Recruiting
Second Xiangya Hospital of Central South University
Not applicable
400
Beijing, Quanzhou, Shenzhen, Tangshan, Luoyang, Wuhan, Changsha, Shenyang
2025-08-18
Recruiting
Jiangsu BioJeTay Biotechnology Co., Ltd.
Phase 1/2
56
Bengbu, Beijing, Tangshan, Zhengzhou, Nanchang, Xi’an, Tianjin
2025-05-12
Recruiting
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1/2
194
Hefei, Beijing, Fuzhou, Lanzhou, Wuwei, Shenzhen, Nanning, Tangshan
2025-04-08
Recruiting
Huazhong University of Science and Technology
Not applicable
2,500
Nanning, Tangshan, Shiyan, Wuhan, Chengdu
2025-04-08
Recruiting
Gritgen Therapeutics Co., Ltd.
Phase 3
50
Hefei, Beijing, Lanzhou, Guangzhou, Tangshan, Zhengzhou, Wuhan, Changsha
2025-03-31
Active, closed
Jiangsu BioJeTay Biotechnology Co., Ltd.
Phase 3
40
Hefei, Lanzhou, Guangzhou, Shenzhen, Nanning, Tangshan, Harbin, Zhengzhou
2025-03-26
Recruiting
Nanjing RegeneCore Biotech Co., Ltd.
Phase 1
71
Hefei, Guangzhou, Shenzhen, Guilin, Nanning, Baoding, Tangshan, Zhengzhou
2025-03-25
Not yet open
Inflammatory and Metabolic Prognostic Assessment in Critically Ill Neurological Patients
NCT06849011Stroke Acute, Encephalitis, Non-traumatic Brain Injury
Yan Zhang
Observational
1,185
Beijing, Lanzhou, Guiyang, Zunyi, Tangshan, Shijiazhuang, Hohhot, Suzhou
2025-03-01
Recruiting
CASI pharmaceuticals, Inc.
Phase 1/2
75
Tangshan, Zhengzhou, Nanchang, Jinan, Tianjin, Kunming
2025-01-03
Recruiting
yilong Wang
Not applicable
134
Wuhu, Beijing, Tangshan, Xi'an, Tianjin
2024-04-22
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2
92
Guangzhou, Nanning, Cangzhou, Chengde, Tangshan, Xingtai, Harbin, Zhengzhou
2023-12-12
Recruiting
Early Initiation of Tafolecimab for Patients With Acute Coronary Syndromeundergoing Percutaneous Coronary Intervention in Chinese Population
NCT06096909Acute Coronary Syndrome, Non ST Segment Elevation Acute Coronary Syndrome, Lipid Lowering, Vascular Inflammation
DrugTafolecimab
China National Center for Cardiovascular Diseases
Phase 4
3,684
Beijing, Tangshan
2023-11-11
Active, closed
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
165
Beijing, Lanzhou, Tangshan, Shanghai, Tianjin
2023-09-21
Recruiting
Green Valley (Shanghai) Pharmaceuticals Co., Ltd.
Phase 4
1,312
Huainan, Beijing, Xiamen, Guangzhou, Shenzhen, Nanning, Shijiazhuang, Tangshan
2023-08-31
Active, closed
Peking University Hospital of Stomatology
Phase 2
110
Beijing, Baoding, Tangshan, Harbin, Chifeng, Hohhot, Changchun, Shenyang
2023-06-27
Active, closed
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
NCT05739383Primary Prevention of Atherosclerotic Cardiovascular Disease
DrugInclisiran
Novartis Pharmaceuticals
Phase 3
14,012
Guangzhou, Nanning, Cangzhou, Shijiazhuang, Tangshan, Xingtai, Daqing, Harbin
2023-03-09
Recruiting
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
400
Fuzhou, Lanzhou, Guangzhou, Meizhou, Haikou, Chengde, Tangshan, Harbin
2022-10-24
Active, closed
European Myeloma Network B.V.
Phase 3
1,594
Beijing, Changchun, Henan, Shandong, Shanghai, Shenyang, Tangshan, Tianjin
2022-09-08
Recruiting
Beijing Friendship Hospital
Observational
1,000
Beijing, Tangshan
2022-08-01
Active, closed
Shanghai Xinzhi BioMed Co., Ltd.
Phase 2/3
32
Hefei, Beijing, Guangzhou, Shenzhen, Tangshan, Zhengzhou, Taiyuan, Tianjin
2021-12-30
Recruiting
Drug Eluting Stenting and Aggressive Medical Treatment for Preventing Recurrent Stroke in Intracranial Atherosclerotic Disease Trial
NCT04948749ICAD - Intracranial Atherosclerotic Disease, ICAS - Intracranial Atherosclerosis, Drug-eluting Stent, Stroke
Beijing Tiantan Hospital
Not applicable
358
Beijing, Cangzhou, Tangshan, Xingtai, Wuhan, Baotou, Hohhot, Tongliao
2021-07-02
Rows per page Showing 1–35 of 35
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 15 November 2026. https://priyalifescience.com/clinical-trials-china/city/tangshan

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,282 studies in total at the last sync on 15 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 35 of those studies with a site in Tangshan.

How many clinical trials are recruiting in Tangshan?

23 of the 35 studies on this page are recruiting new participants as of the 15 Nov 2026, 03:17 UTC sync. A further 5 have not yet opened recruitment, 7 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Tangshan), 35 studies
PhaseStudiesRecruitingShare
Phase 310428.6%
Not applicable5514.3%
Phase 25314.3%
Phase 45414.3%
Phase 1/24411.4%
Observational318.6%
Phase 1225.7%
Phase 2/3102.9%

Most active sponsors

Lead sponsors with the most studies (Tangshan)
Lead sponsorStudiesRecruiting
Peking Union Medical College Hospital31
Capital Medical University21
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.21
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.22
Jiangsu BioJeTay Biotechnology Co., Ltd.21
Nanjing RegeneCore Biotech Co., Ltd.22
Beijing Friendship Hospital11
Beijing Tiantan Hospital11
CASI pharmaceuticals, Inc.11
China National Center for Cardiovascular Diseases11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.